M18-969
Recruiting
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The primary objective is to assess the safety and efficacy of elagolix (150 mg QD) when used concurrently with a COC containing an estrogen and a progesterone in premenopausal women with endometriosis and associated moderate to severe pain.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 848407
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
